Metagenomi Therapeutics, Inc. (MGX)

NASDAQ: MGX · Real-Time Price · USD

1.390

+0.020 (1.46%)

At close: Mar 25, 2026, 4:00 PM EDT

1.400

+0.010 (0.72%)

After-hours: Mar 25, 2026, 5:26 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Developing Curative Therapeutics for Patients	25.21M	52.30M	44.76M	17.20M	243.00K
Developing Curative Therapeutics for Patients Growth	-51.79%	16.84%	160.21%	6978.19%	-
Total	25.21M	52.30M	44.76M	17.20M	243.00K
Total Growth	-51.79%	16.84%	160.21%	6978.19%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
United States	25.21M	52.30M	44.76M	17.20M	243.00K
United States Growth	-51.79%	16.84%	160.21%	6978.19%	-
Total	25.21M	52.30M	44.76M	17.20M	243.00K
Total Growth	-51.79%	16.84%	160.21%	6978.19%	-

Source: S&P Global Market Intelligence.